John H. Johnson


Mr. Johnson has served as a member of our Board of Directors since July 2021. He currently serves as the Chief Executive Officer of Strongbridge Biopharma plc., a company focused on building a portfolio of vertical, therapeutically-aligned rare disease franchises, a position he has held since July 2020. He served as the company’s Executive Chairman from March 2015 to November 2019. Mr. Johnson previously served as the Chief Executive Officer of Melinta Therapeutics, a commercial stage company developing and commercializing novel antibiotics, from 2018 until 2020. He served as Chairman and Chief Executive Officer of Dendreon Corporation from 2012 until 2014. Mr. Johnson previously held various senior positions with Eli Lilly & Company, ImClone Systems, Inc., Johnson & Johnson, and Centocor Ortho Biotech. Mr. Johnson currently serves as non-executive chairman of the board for Autolus Therapeutics plc (NASDAQ: AUTL), on the Board of Directors of Strongbridge Biopharma, Verastem Oncology, and BioAgilytix. Mr. Johnson received his B.S. degree from East Stroudsburg University of Pennsylvania.